MPs want biotech watchdog
Monday 17 August 1998
The regulator's main task would be to vet public statements made by companies on the progress of their drugs' clinical trials to make sure they are not misleading. The move is designed to restore confidence in biotechnology companies in the financial community following the British Biotech scandal.
In their long-awaited report on the affair, due to be published today, the Science and Technology Select Committee will also call for a code requiring pharmaceutical companies to appoint at least one non-executive director with scientific experience to the board.
The all-party group of MPs is set to argue that the measures are needed to avoid a repeat of the scandal engulfing British Biotech, the UK's largest biotechnology group.
For the past five months, the troubled company has been riven by a bitter feud between its outgoing chief executive Dr Keith McCullagh and its former head of clinical trials, Dr Andrew Millar.
Dr Millar has alleged that the board of British Biotech, led by Dr McCullagh, issued overoptimistic press statements on two of the company's star drugs. The company has repeatedly refuted the allegations and has accused Dr Millar of lifting the secrecy on some of the drugs' trials. Dr Millar was sacked in April after airing his concerns to one institutional shareholder.
The scandal has undermined investors' confidence in the whole sector, leading to a sharp fall in the prices of biotechnology stocks and hindering many companies' ability to raise cash on the stock market. Biotechnology companies need external funds to pay for development costs because their balance sheets tend to remain in the red until a drug is successfully launched on to themarket.
After a three-month inquiry into the implications for the industry, the MPs concluded that the appointment of an independent regulator and directors with scientific knowledge were crucial to restore investors' confidence, and help fledgling companies to raise research cash.
They will call for the rapid implementation of measures to prevent any lasting damage to the industry. Sources close to the committee said yesterday that the MPs believed that the events at British Biotech were partly the result of a lax regulatory regime.
"They (the MPs) don't think that the regulatory system is adequate at the moment. There is clearly a need for a tighter framework," the sources said.
They added that a regulator could help ease the "tension between the companies' need to keep investors informed and the urge to issue optimistic statements on their products".
The appointment to the board of at least one non-executive director with pharmaceutical experience would also contribute to solve the problem. The idea was first mooted by Peter Lewis, British Biotech's former head of research, in evidence to the committee. The committee accepted the idea because, said the sources, "the MPs have some reservations on the knowledge base of non-executive directors. Boards need to count on someone who is scientifically proficient."
The report will also criticise the British Biotech's board for their handling of the affair, while Dr Millar is said toemerge largely unscathed.
- 1 Howard Jacobson: Let's see the 'criticism' of Israel for what it really is
- 2 Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
- 4 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
Gingers face extinction due to climate change, scientists warn
Mick Jagger denies being World Cup curse and reason for Brazil’s embarrassing defeat
Do you know this man? Amnesia sufferer found in park pleads for help in identifying who he is
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
There’s a nasty smell in the political air – and it’s coming from the Tories
Vanessa Feltz criticises 'vile' reaction to Rolf Harris allegations
iJobs Money & Business
£60000 - £75000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£60000 per annum: Harrington Starr: A leading provider in investment managemen...
£600 - £700 per day: Harrington Starr: AVS, JVS Openlink Endur Developer JVS, ...
£30000 per annum: Harrington Starr: A global leader in trading platforms and e...